{"entity":{"id":"mtx240","kind":"drug","name":"MTX240","aka":["OPB-171775"],"tldr":"MTX240 is an early drug from Biodexa Pharmaceuticals for gastrointestinal stromal tumour that kills tumour cells by a route that does not depend on the KIT protein, which matters once standard tablets stop working.","summary":"MTX240, formerly OPB-171775, was licensed by Biodexa Pharmaceuticals from Otsuka in February 2026. Otsuka assembled a preclinical package and obtained approval for a phase 1 study from Japan's PMDA. Biodexa's first priorities are clinical trial manufacturing, an IND filing and a phase 1b/2a dose-escalation study in GIST, including tumours resistant to tyrosine kinase inhibitors.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"SEC: Biodexa Pharmaceuticals Form F-1, September 2026","url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926011934/y917262f1.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["molecular-glue-platforms"],"targets":[],"drugs":[],"companies":["biodexa-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"MTX240","modality":"Small-molecule molecular glue","mechanism":"A molecular glue that brings together PDE3A and SLFN12, co-expressed in GIST cells, stabilising SLFN12 so that it drives RNase-mediated cell death independently of KIT signalling, as described by Biodexa Pharmaceuticals.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mtx240/","neighbours":{"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"}],"company":[{"id":"biodexa-pharmaceuticals","kind":"company","name":"Biodexa Pharmaceuticals","route":"/companies/biodexa-pharmaceuticals/"}]}}